Physician
Summit Medical Group, PLLC
Summit Medical Group, PLLC was paid $44.61M by Medicaid between Jan 2018 and Dec 2024, across 212 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoSUMMIT MEDICAL GROUP, PLLC
KNOXVILLE, TN 37909
KNOXVILLE, TN 37909
33aNPI1548349186assigned 11/03/2006
33bProvider typeFamily Medicine Physician
28Total paid$44.61M
24GClaims1,463,996
24DCodes billed212
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Tennessee
Rank by total paid#1 of 754
Median peer was paid$34K
This provider vs. median1,321×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 153,300 | $4.22M | |
| 2019 | 203,549 | $6.21M | |
| 2020 | 176,017 | $5.25M | |
| 2021 | 218,159 | $6.71M | |
| 2022 | 232,909 | $7.33M | |
| 2023 | 256,224 | $7.86M | |
| 2024incomplete | 223,838 | $7.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 369,212 | 315,328 | $15.64M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 158,661 | 125,771 | $7.54M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.6% | 65,948 | 57,716 | $3.41M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.1% | 33,749 | 30,865 | $2.70M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.0% | 31,626 | 27,070 | $2.22M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.1% | 23,188 | 21,301 | $1.84M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.1% | 46,159 | 42,800 | $1.81M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.8% | 17,882 | 16,277 | $1.71M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 23,028 | 21,055 | $1.08M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.8% | 9,329 | 8,179 | $809K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.7% | 26,835 | 24,263 | $765K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,009 | 2,705 | $387K |
200 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 9,824 | $307K |
| 92551 | <1% | 29,233 | $242K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,784 | $236K |
| 87428 | <1% | 4,250 | $232K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,862 | $221K |
| 80061 | Lipid panel | <1% | 22,037 | $202K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15,190 | $186K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,559 | $180K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,238 | $168K |
| 96161 | <1% | 16,374 | $167K | |
| 96127 | <1% | 29,859 | $158K | |
| 99177 | <1% | 21,637 | $155K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 109,039 | $147K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,827 | $136K |
| 80050 | General health panel | <1% | 4,218 | $123K |
| 96160 | <1% | 15,439 | $122K | |
| 80053 | Comprehensive metabolic panel | <1% | 21,063 | $112K |
| 99173 | <1% | 18,170 | $98K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,631 | $97K |
| 99381 | <1% | 1,189 | $88K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,164 | $74K |
| 83655 | <1% | 4,208 | $62K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,559 | $60K |
| 90686 | <1% | 18,962 | $43K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 786 | $41K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 631 | $41K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 520 | $41K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 813 | $41K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,381 | $41K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 3,270 | $40K |
| 36416 | <1% | 27,286 | $40K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,762 | $38K |
| 87634 | <1% | 536 | $38K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 346 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,682 | $34K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 793 | $28K |
| 95886 | <1% | 575 | $28K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,852 | $28K |
| 87430 | <1% | 2,141 | $28K | |
| 81003 | <1% | 14,483 | $27K | |
| 90670 | <1% | 16,672 | $25K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 325 | $23K |
| 92015 | Determination of refractive state | <1% | 856 | $23K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,057 | $19K |
| 85027 | <1% | 4,249 | $17K | |
| 90651 | <1% | 2,929 | $16K | |
| 90461 | <1% | 34,874 | $15K | |
| 99174 | <1% | 1,199 | $14K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 2,503 | $14K |
| 88720 | <1% | 2,333 | $13K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 452 | $12K |
| 90688 | <1% | 3,536 | $12K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,465 | $11K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 435 | $10K |
| 84439 | <1% | 1,117 | $10K | |
| 90837 | Psychotherapy session, about an hour | <1% | 178 | $9K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 264 | $9K |
| 92552 | <1% | 427 | $8K | |
| 87631 | <1% | 87 | $8K | |
| 99307 | <1% | 1,197 | $8K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 604 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 236 | $7K |
| 87807 | <1% | 567 | $7K | |
| 84466 | <1% | 582 | $7K | |
| 90674 | <1% | 808 | $7K | |
| 99383 | <1% | 88 | $7K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 378 | $7K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 368 | $6K |
| 82728 | <1% | 486 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 390 | $6K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 666 | $6K |
| 83525 | <1% | 497 | $6K | |
| 99223 | Prolong inpt eval add15 m | <1% | 98 | $6K |
| 90723 | <1% | 14,110 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 247 | $5K |
| 82607 | <1% | 419 | $5K | |
| 90734 | <1% | 1,541 | $5K | |
| 90756 | <1% | 374 | $5K | |
| 92136 | <1% | 689 | $5K | |
| 90716 | <1% | 1,942 | $5K | |
| 90633 | <1% | 7,688 | $4K | |
| 99382 | <1% | 86 | $4K | |
| 90710 | <1% | 907 | $4K | |
| 90739 | <1% | 26 | $4K | |
| 90680 | <1% | 12,455 | $4K | |
| 83540 | <1% | 626 | $4K | |
| 84681 | <1% | 161 | $4K | |
| 0012A | <1% | 108 | $4K | |
| 96380 | <1% | 180 | $4K | |
| 86803 | <1% | 254 | $4K | |
| 92134 | <1% | 437 | $3K | |
| 90707 | <1% | 1,962 | $3K | |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 167 | $3K |
| 82465 | <1% | 976 | $3K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 836 | $3K |
| V2020 | Frames, purchases | <1% | 194 | $3K |
| 99441 | <1% | 254 | $3K | |
| 99051 | <1% | 812 | $3K | |
| 90746 | <1% | 40 | $3K | |
| 0011A | <1% | 77 | $3K | |
| 0001A | <1% | 117 | $2K | |
| 90661 | <1% | 1,798 | $2K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 105 | $2K |
| 0002A | <1% | 83 | $2K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 3,350 | $2K |
| 69210 | <1% | 78 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 21 | $2K |
| 90715 | <1% | 353 | $2K | |
| 94760 | <1% | 3,775 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 47 | $2K |
| 87081 | <1% | 315 | $2K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 33 | $2K |
| 90648 | <1% | 16,087 | $2K | |
| 90671 | <1% | 3,907 | $1K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 29 | $1K |
| 0071A | <1% | 54 | $1K | |
| 91320 | <1% | 21 | $1K | |
| 82962 | <1% | 1,289 | $1K | |
| 0072A | <1% | 36 | $1K | |
| 85018 | <1% | 351 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 93 | $1K |
| 90696 | <1% | 945 | $1K | |
| 99406 | <1% | 141 | $1K | |
| 90677 | <1% | 454 | $1K | |
| 99384 | <1% | 16 | $996.54 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 14 | $962.57 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 1,233 | $945.02 |
| 97161 | <1% | 14 | $942.67 | |
| 86140 | <1% | 419 | $806.38 | |
| 99497 | <1% | 14 | $793.06 | |
| 87420 | <1% | 62 | $786.45 | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 39 | $779.07 |
| 92002 | <1% | 12 | $747.46 | |
| 93000 | <1% | 65 | $581.91 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 24 | $572.16 |
| 82570 | <1% | 280 | $561.27 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $560.90 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $560.84 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 151 | $496.85 |
| 90658 | <1% | 38 | $476.16 | |
| 99442 | <1% | 31 | $466.20 | |
| 90647 | <1% | 2,291 | $451.44 | |
| 90620 | <1% | 55 | $436.00 | |
| 99217 | <1% | 12 | $417.83 | |
| 90480 | <1% | 19 | $369.69 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,543 | $369.38 |
| 94761 | <1% | 43 | $366.20 | |
| 82044 | <1% | 256 | $365.55 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 46 | $325.91 |
| 82550 | <1% | 66 | $260.93 | |
| 83735 | <1% | 62 | $260.09 | |
| 82746 | <1% | 34 | $258.43 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 131 | $198.50 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 967 | $196.99 |
| 90672 | <1% | 105 | $178.71 | |
| 85652 | <1% | 161 | $171.76 | |
| 90474 | <1% | 29 | $169.33 | |
| 99318 | <1% | 18 | $166.54 | |
| 81025 | <1% | 18 | $146.98 | |
| 90656 | <1% | 482 | $137.51 | |
| 90700 | <1% | 515 | $133.45 | |
| 90630 | <1% | 25 | $125.90 | |
| 81001 | <1% | 42 | $115.92 | |
| 83721 | <1% | 39 | $110.64 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 15 | $105.02 |
| 90660 | <1% | 67 | $86.55 | |
| 82043 | <1% | 31 | $85.06 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 304 | $81.58 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 182 | $75.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 115 | $74.73 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 15 | $56.86 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 20 | $41.21 |
| 0064A | <1% | 18 | $40.00 | |
| J3490 | Unclassified drugs | <1% | 19 | $30.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 165 | $12.14 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13 | $9.64 |
| 91300 | <1% | 40 | $0.19 | |
| 1159F | <1% | 610 | $0.02 | |
| 91307 | <1% | 37 | $0.01 | |
| 3008F | 0% | 101 | $0.00 | |
| 99000 | 0% | 925 | $0.00 | |
| 90698 | 0% | 666 | $0.00 | |
| 90744 | 0% | 311 | $0.00 | |
| 1170F | 0% | 583 | $0.00 | |
| 1111F | 0% | 1,293 | $0.00 | |
| 90694 | 0% | 56 | $0.00 | |
| 90381 | 0% | 35 | $0.00 | |
| 3074F | 0% | 58 | $0.00 | |
| 90619 | 0% | 16 | $0.00 | |
| 2023F | 0% | 32 | $0.00 | |
| 99397 | 0% | 363 | $0.00 | |
| 90685 | 0% | 497 | $0.00 | |
| 1160F | 0% | 218 | $0.00 | |
| 90687 | 0% | 354 | $0.00 | |
| 90380 | 0% | 17 | $0.00 | |
| 99072 | 0% | 73 | $0.00 | |
| 90662 | 0% | 397 | $0.00 | |
| 99499 | 0% | 107 | $0.00 | |
| 3078F | 0% | 58 | $0.00 | |
| 90681 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCURTIS, ED (CHIEF ADMINISTRATIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Summit Medical Group,pllc | Jefferson City, TN | $10K |
| Summit Medical Group, PLLC | Kingston, TN | $2K |
| Summit Medical Group, PLLC | La Follette, TN | $924.79 |
| Summit Medical Group, PLLC | Knoxville, TN | $349.80 |
| Summit Medical Group, PLLC | Clinton, TN | $236.21 |
| Summit Medical Group, PLLC | Greeneville, TN | $65.47 |
| Summit Medical Group, PLLC | Knoxville, TN | $54.44 |
| Summit Medical Group, PLLC | Knoxville, TN | $0.00 |
| Summit Medical Group, PLLC | Maynardville, TN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.